Tonix Pharmaceuticals Holding Corp.
TNXP
$15.52
$0.301.97%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -8.79% | -21.09% | -2.04% | 29.94% | 183.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.79% | -21.09% | -2.04% | 29.94% | 183.05% |
| Cost of Revenue | -24.40% | -28.82% | 10.11% | 63.78% | 276.96% |
| Gross Profit | 50.90% | 6.99% | -22.24% | -23.06% | 45.02% |
| SG&A Expenses | 87.02% | 33.52% | 11.52% | 15.40% | 15.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.37% | -14.33% | -28.94% | -30.37% | -26.52% |
| Operating Income | -20.95% | 13.45% | 31.54% | 34.33% | 33.27% |
| Income Before Tax | 26.64% | 45.36% | -33.81% | -11.47% | -11.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.64% | 45.36% | -33.81% | -11.47% | -11.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.64% | 45.36% | -33.81% | -11.47% | -11.76% |
| EBIT | -20.95% | 13.45% | 31.54% | 34.33% | 33.27% |
| EBITDA | -23.92% | 11.97% | 31.41% | 34.83% | 34.52% |
| EPS Basic | 99.57% | 99.16% | 27.97% | -14.18% | -- |
| Normalized Basic EPS | 98.11% | 96.19% | 3.27% | -- | -- |
| EPS Diluted | 99.57% | 99.16% | 27.97% | -14.18% | -- |
| Normalized Diluted EPS | 98.11% | 96.19% | 3.27% | -- | -- |
| Average Basic Shares Outstanding | 3,413.63% | 23,332.08% | 31,650.54% | -- | -- |
| Average Diluted Shares Outstanding | 3,351.60% | 19,733.78% | 21,826.73% | 23,572.80% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |